HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe pneumocystis pneumonia in solid organ transplant recipients.

AbstractBACKGROUND:
Pneumocystis jiroveci pneumonia may be a life-threatening opportunistic infection in immunosuppressed solid organ transplant recipients. Despite effective treatment with high-dose trimethoprim-sulfamethoxazole and steroids, morbidity is often severe and lethality remains high. New therapeutic approaches are therefore warranted. Caspofungin, a beta-1,3-glucan synthesis inhibitor, has shown activity against the cyst forms of P. jiroveci in experimental animal models. We here report our preliminary clinical experience with caspofungin as an additional drug to the standard trimethoprim-sulfamethoxazole regimen.
METHODS:
Four solid organ transplant patients with severe hypoxemic P. jiroveci pneumonia were treated with the combination of trimethoprim-sulfametoxazole and caspofungin. In two cases, caspofungin was added as salvage treatment due to failure of trimethoprim-sulfametoxazole monotherapy.
RESULTS:
In these four patients, the use of caspofungin as an additional drug to the standard trimethoprim-sulfamethoxazole regimen led to a rapid improvement and a complete cure of pneumonia. No side effects or drug interactions were observed.
DISCUSSION:
This preliminary clinical experience suggests that the addition of caspofungin to trimethoprim-sulfamethoxazole, which is active against trophic forms, may provide a synergistic activity against P. jiroveci by fully inhibiting the organism life cycle.
AuthorsRiccardo Utili, Emanuele Durante-Mangoni, Cristina Basilico, Annunziata Mattei, Enrico Ragone, Paolo Grossi
JournalTransplantation (Transplantation) Vol. 84 Issue 6 Pg. 685-8 (Sep 27 2007) ISSN: 0041-1337 [Print] United States
PMID17893600 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Infective Agents
  • Echinocandins
  • Lipopeptides
  • Peptides, Cyclic
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Caspofungin
Topics
  • Adult
  • Anti-Infective Agents (therapeutic use)
  • Caspofungin
  • Drug Therapy, Combination
  • Echinocandins
  • Female
  • Humans
  • Immunosuppression Therapy (adverse effects)
  • Lipopeptides
  • Male
  • Middle Aged
  • Organ Transplantation
  • Peptides, Cyclic (therapeutic use)
  • Pneumonia, Pneumocystis (drug therapy, immunology)
  • Treatment Outcome
  • Trimethoprim, Sulfamethoxazole Drug Combination (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: